bearish
CanSino Biologics (康希诺) IPO: Promising Pre-Clinical Results but Vaccine Scandal Weighs (Part 1)
789 Views25 Oct 2018 08:06
CanSino Biologics, a vaccine-focused biotech company, is planning to seek up to USD 150 million via a listing on the Hong Kong Stock Exchange.
In...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 11-minute read)
Discussions
(Paid Plans Only)
- CanSino Biologics (康希诺) IPO: Promising Pre-Clinical Results but Vaccine Scandal Weighs (Part 1)25 Oct 2018
- Okja: The Fight Between Netflix Vs. CJ CGV05 Jun 2017
- Netflix & Amazon Expand in Korea – Not a Coincidence20 Jan 2016
- Thoughts on Amazon –What Does Its Valuation Tells Us?01 Dec 2015
x